Society for Clinical Research Sites Welcomes Center Point Clinical Services as New Global Impact Partner
Ellicott City, M.D., June 8, 2015 – The Society for Clinical Research Sites (SCRS), the global trade organization fully dedicated to representing the interests of clinical research sites, today announced a two-year relationship with Center Point Clinical Services, a specialty service provider working to improve critical factors in successful clinical trials, including patient satisfaction, retention, and compliance. Center Point will participate as a Global Impact Partner (GIP) and align with 30 other sponsors, CROs, and service providers dedicated to promoting high-level communication and meaningful collaboration between industry stakeholders and clinical research sites globally.
“Center Point’s commitment to focus on the enhancement of pivotal facets of clinical trials lays the foundation for a strong relationship with SCRS, and therefore clinical research sites globally,” comments Christine Pierre, SCRS President. “SCRS is proud to welcome them to our community, and commends them for their dedication to promoting site sustainability across the clinical research enterprise.”
“Center Point is pleased to join SCRS and to share in its mission to create a unified voice for the clinical research community,” said Gerald Finken, CEO, Center Point. “At Center Point, we strive to truly listen to our patients and to work with sites to deliver the best possible care. Serving as a Global Impact Partner with SCRS and clinical sites will provide us with crucial new perspectives to better understand the needs of our patients.”
As a Global Impact Partner, Center Point will participate on the SCRS Global Impact Board at an executive level, and work closely with SCRS’ Leadership Council to determine strategic initiatives for SCRS.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
